The Dutch registry for facioscapulohumeral muscular dystrophy : Cohort profile and longitudinal patient reported outcomes
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved..
Facioscapulohumeral dystrophy (FSHD) is the second most prevalent inherited muscular disorder and currently lacks a pharmaceutical treatment. The Dutch FSHD Registry was initiated in 2015 as a result of an international collaboration on trial readiness. This paper presents the cohort profile and six years of follow-up data of the registered FSHD patients. At the time of self-registration and every six months thereafter, participants were invited to complete a digital survey of patient and disease characteristics and the Dutch versions of the Checklist Individual Strength (CIS20R), the Individualised Neuromuscular Quality of Life Questionnaire (INQoL), the Beck Depression Index - Primary Care and the McGill Pain Questionnaire. From March 2015 to March 2021, 373 participants completed at least one survey. At baseline, fatigue and muscle weakness were the most frequently reported symptoms (median CIS20R sumscore 77 [IQR 60-92], median INQoL Fatigue score 58 [IQR 42-68] and median INQoL weakness score 58 [IQR 42-68]). Pain was experienced most often in the head and shoulder region (193, 52%). Nineteen of the 23 (sub)sections of questionnaires showed no significant changes over time. We conclude that the Dutch FSHD Registry was successfully set up, enabling collection of longitudinal data and facilitating recruitment in several studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
Neuromuscular disorders : NMD - 33(2023), 12 vom: 12. Dez., Seite 964-971 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kools, Joost [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Facioscapulohumeral muscular dystrophy |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 16.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.nmd.2023.10.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365080411 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365080411 | ||
| 003 | DE-627 | ||
| 005 | 20231227133809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.nmd.2023.10.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1231.xml |
| 035 | |a (DE-627)NLM365080411 | ||
| 035 | |a (NLM)38016873 | ||
| 035 | |a (PII)S0960-8966(23)00773-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kools, Joost |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Dutch registry for facioscapulohumeral muscular dystrophy |b Cohort profile and longitudinal patient reported outcomes |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 16.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Facioscapulohumeral dystrophy (FSHD) is the second most prevalent inherited muscular disorder and currently lacks a pharmaceutical treatment. The Dutch FSHD Registry was initiated in 2015 as a result of an international collaboration on trial readiness. This paper presents the cohort profile and six years of follow-up data of the registered FSHD patients. At the time of self-registration and every six months thereafter, participants were invited to complete a digital survey of patient and disease characteristics and the Dutch versions of the Checklist Individual Strength (CIS20R), the Individualised Neuromuscular Quality of Life Questionnaire (INQoL), the Beck Depression Index - Primary Care and the McGill Pain Questionnaire. From March 2015 to March 2021, 373 participants completed at least one survey. At baseline, fatigue and muscle weakness were the most frequently reported symptoms (median CIS20R sumscore 77 [IQR 60-92], median INQoL Fatigue score 58 [IQR 42-68] and median INQoL weakness score 58 [IQR 42-68]). Pain was experienced most often in the head and shoulder region (193, 52%). Nineteen of the 23 (sub)sections of questionnaires showed no significant changes over time. We conclude that the Dutch FSHD Registry was successfully set up, enabling collection of longitudinal data and facilitating recruitment in several studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Facioscapulohumeral muscular dystrophy | |
| 650 | 4 | |a Longitudinal prospective cohort | |
| 650 | 4 | |a Patient reported outcome measure | |
| 650 | 4 | |a Registry | |
| 700 | 1 | |a Deenen, Johanna Cw |e verfasserin |4 aut | |
| 700 | 1 | |a Blokhuis, Anna M |e verfasserin |4 aut | |
| 700 | 1 | |a Verbeek, André Lm |e verfasserin |4 aut | |
| 700 | 1 | |a Voermans, Nicol C |e verfasserin |4 aut | |
| 700 | 1 | |a van Engelen, Baziel Gm |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuromuscular disorders : NMD |d 1993 |g 33(2023), 12 vom: 12. Dez., Seite 964-971 |w (DE-627)NLM012649740 |x 1873-2364 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2023 |g number:12 |g day:12 |g month:12 |g pages:964-971 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nmd.2023.10.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2023 |e 12 |b 12 |c 12 |h 964-971 | ||